Abstract
New agents for the treatment of acute myelogenous leukemia are discussed that reflect different treatment mechanisms. These include histone acetylation, angiogenesis inhibition, protein kinase inhibitors, and a novel retinoid. Efficacy and safety in phase I and phase II trials reviewed, as well as the problems involved in crossing over from treatment of solid tumors to blood disorders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM . Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 1998 391: 811–814
Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG . Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia Nature 1998 391: 815–818
He LZ, Guidez F, Tribioli C et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with corepressors determine differential responses to RA in APL Nat Genet 1998 18: 126–135
David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A . Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein Oncogene 1998 16: 2549–2556
Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A . Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia Blood 1998 91: 2634–2642
Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA . Aberrant recruitment of the nuclear receptor corepressor–histone deacetylase complex by the acute myeloid leukemia fusion partner ETO Mol Cell Biol 1998 18: 7185–7191
Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW . ETO, a target of t (8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors Mol Cell Biol 1998 18: 7176–7184
Collins SJ . Acute promyelocytic leukemia: relieving repression induces remission Blood 1998 91: 2631–2633
Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM . ETO, fusion partner in t (8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex Proc Natl Acad Sci USA 1998 95: 10860–10865
Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR . Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells Blood 1999 94: 1401–1408
Lea MA, Tulsyan N . Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase Anticancer Res 1995 15: 879–883
Yu KH, Weng LJ, Fu S, Piantadosi S, Gore SD . Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid Leukemia 1999 13: 1258–1265
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A . Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 1998 393: 386–389
Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP . Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nat Genet 1998 19: 187–191
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB . Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 1999 21: 103–107
Folkman J . Tumor angiogenesis: therapeutic implications New Engl J Med 1971 285: 1182–1186
Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J . Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers J Natl Cancer Inst 1994 86: 356–361
Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J . Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 1997 150: 815–821
Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK . Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia Blood 1997 89: 1870–1875
Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S . Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2 Mol Pharmacol 1997 52: 1000–1009
Liu G, Wu M, Levi G, Ferrari N . Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression Int J Cancer 1998 78: 248–254
Reed JC . Fenretinide: the death of a tumor cell J Natl Cancer Inst 1999 91: 1099–1100
Sun SY, Yue P, Lotan R . Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retionic acid receptors, and apoptosis-related genes in human prostate carcinoma cells Mol Pharmacol 1999 55: 403–410
Bagniewski PG, Reid JM, Villablanca JG, Reynolds CP, Ames MM . A phase I pharmacokinetic study of fenretinide in children with high-risk solid tumors AACR Proc 1999 40: 92
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zwiebel, J. New agents for acute myelogenous leukemia. Leukemia 14, 488–490 (2000). https://doi.org/10.1038/sj.leu.2401662
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401662
Keywords
This article is cited by
-
Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia
Leukemia (2003)
-
Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1α
Leukemia (2003)
-
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia
Leukemia (2002)
-
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective
Leukemia (2002)